Although confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with hosts provides a significant number of potential drug targets and the potential to repurpose drugs already tested in other diseases. Herein, we report the biological rationale of immune-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immunocompetence.

Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019 / S. Di Cosimo, A. Malfettone, J.M. Perez-Garcia, A. Llombart-Cussac, R. Miceli, G. Curigliano, J. Cortes. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 135(2020), pp. 62-65. [10.1016/j.ejca.2020.05.026]

Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019

G. Curigliano
Conceptualization
;
2020

Abstract

Although confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with hosts provides a significant number of potential drug targets and the potential to repurpose drugs already tested in other diseases. Herein, we report the biological rationale of immune-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immunocompetence.
Anti–IL-6R; Anti–PD-1; COVID-19; Cytokine storm; Pembrolizumab; SARS-CoV-2; Tocilizumab; Antibodies, Monoclonal, Humanized; Apoptosis; B7-H1 Antigen; Betacoronavirus; COVID-19; Coronavirus Infections; Host-Pathogen Interactions; Humans; Immunologic Factors; Lymphopenia; Neoplasms; Pandemics; Pneumonia, Viral; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; SARS-CoV-2; T-Lymphocytes; Treatment Outcome
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Di Cosimo and Curigliano EJC.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 260.09 kB
Formato Adobe PDF
260.09 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/824759
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 24
social impact